296 related articles for article (PubMed ID: 34728570)
1. Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.
Farah E; Zhang Z; Utturkar SM; Liu J; Ratliff TL; Liu X
Mol Cancer Ther; 2022 Jan; 21(1):193-205. PubMed ID: 34728570
[TBL] [Abstract][Full Text] [Related]
2. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
Kohrt SE; Awadallah WN; Phillips RA; Case TC; Jin R; Nanda JS; Yu X; Clark PE; Yi Y; Matusik RJ; Anderson PD; Grabowska MM
Mol Cancer Ther; 2021 Feb; 20(2):398-409. PubMed ID: 33298586
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
4. Loss of Long Noncoding RNA
Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
6. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.
Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W
Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063
[TBL] [Abstract][Full Text] [Related]
7. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
[TBL] [Abstract][Full Text] [Related]
8. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes.
Feng T; Wei D; Zhao J; Li Q; Guo P; Yang X; Li M; Jiang Y; Luo Y
Exp Biol Med (Maywood); 2021 Aug; 246(15):1776-1787. PubMed ID: 34034559
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models.
Schmidt KT; Chau CH; Strope JD; Huitema ADR; Sissung TM; Price DK; Figg WD
Mol Cancer Ther; 2021 May; 20(5):915-924. PubMed ID: 33632874
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
11. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
12. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract][Full Text] [Related]
13. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
15. Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
Tang D; He J; Dai Y; Geng X; Leng Q; Jiang H; Sun R; Xu S
Cancer Gene Ther; 2022 May; 29(5):543-557. PubMed ID: 33854217
[TBL] [Abstract][Full Text] [Related]
16. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.
Farah E; Li C; Cheng L; Kong Y; Lanman NA; Pascuzzi P; Lorenz GR; Zhang Y; Ahmad N; Li L; Ratliff T; Liu X
J Biol Chem; 2019 May; 294(21):8543-8554. PubMed ID: 30940724
[TBL] [Abstract][Full Text] [Related]
17. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
18. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
[TBL] [Abstract][Full Text] [Related]
19. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
